Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 linzagolix study in moderate to severe endometriosis-associated pain
2019-000283-26Phase 3Completed
- Sponsor
- ObsEva SA
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of linzagolix in endometriosis (3 arms), sponsored by ObsEva SA. Primary endpoints: Clinically meaningful reduction in dysmenorrhea at Month 3 and Clinically meaningful reduction in non-menstrual pelvic pain at Month 3. Started Jun 2019; status: completed.
02
Drugs
linzagolix
03
Conditions
endometriosis
Beyond the preview
Go deeper on 2019-000283-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000283-26.